Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher
Net Sales are expected to decrease by 0.2 percent Y-o-Y (up 0.1 percent Q-o-Q) to Rs 3,788.1 crore, according to Prabhudas Lilladher.13-01-2022
13-01-2022
CADILA HEALTHCARE LTD. - 532321 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer06-01-2022
CADILA HEALTHCARE LTD. - 532321 - Shareholding for the Period Ended December 31, 2021
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here06-01-2022
CADILA HEALTHCARE LTD. - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 201806-01-2022
Cadila Healthcare's healthy product pipeline adds to earnings visibility
As the extraordinary gains from covid treatment drug sales during the June quarter softened, the high base in the domestic market added to the muted near-term growth expectations04-01-2022
Cadila Healthcare's US arm receives FDA nod to market Pimavanserin capsule
Cadila Healthcare on Friday said its US arm Zydus Pharmaceuticals (USA) Inc has received tentative approval from the US health regulator to market generic Pimavanserin capsules, indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The approval by the US Food & Drug Administration for the generic Pimavanserin capsules is for the strength of 34 mg, Cadila Healthcare said in a regulatory filing. "The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad," it said. The group now has 325 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it added.31-12-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from USFDA for Pimavanserin Capsules31-12-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice of loss of share certificate of the Company, published in the Financial Express on December 31, 202131-12-2021
CADILA HEALTHCARE LTD. - 532321 - Closure of Trading Window
Intimation of Trading Window Closure27-12-2021
Covid-19 vaccine stock-taking: Does India have enough to expand the drive?
Zydus Cadila's yet to be launched DNA plasmid vaccine ZyCoV-D is expected to add to the vaccine supply27-12-2021